FDA has approved expanded claims for the cobas EGFR Mutation Test v2 as a companion diagnostic for a broad group of therapies in the treatment of non-small cell lung cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
